In 2000, GlaxoSmithKline was formed by merging Glaxo Wellcome and SmithKline Beecham. Our full history, however, is extensive, and dates back nearly 2 centuries. Each of the companies that grew into what is now GSK had a simple beginning and was, in its own way, a pioneer in the field of healthcare. Throughout our history, we’ve remained focused on, and committed to, a central theme: changing people’s lives with the latest healthcare developments.

That commitment has enabled us to become what we are today—one of the largest pharmaceutical companies in the world, with over 15,000 researchers working to discover new medicines. [36] In fact, we screen about 65 million compounds every year. Our scientists are working hard to discover new ways to treat illness and disease by using up-to-date technology and collaborating with industry leaders and academic institutions.

Oncology is our most dynamic field. Our firm foundation in science and dedication to research have led to a robust portfolio of products for the reduction in risk and treatment of cancer, as well as patient support. Our commitment to advancing knowledge in this field is best illustrated by the decades-long partnership of Nobel laureates Gertrude Elion and Dr George Hitchings, whose work resulted in new therapeutics to improve the lives of cancer patients. Their findings led to the development of drugs that block nucleic acid synthesis in cancer cells, and resulted in the 1988 Nobel Prize in Physiology or Medicine. [37]

Today, over 60 years after the two began working together, their legacy of dedication and innovation is still evident in our research and development program.

Looking to the future, our researchers will continue to aggressively explore new and evolving scientific frontiers. GSK is fully committed to the research and development of innovative oncology products that will make profound differences in the lives of patients with cancer.

Learn more about:

Symptoms and Treatment Side Effects